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indicator of the influence of the UK in global RW research. METHODS: All 1455
abstracts presented at the ISPOR 14th Annual European Congress in Madrid, Spain
in 2011 were reviewed in THE ISPOR OUTCOMES RESEARCH DIGEST, available via
the ISPOR website. Posters were also reviewed where available. Those reporting RW
studies were classified according to: therapeutic area, type of study, setting, source
of data and methodology, country undertaken, country of authors and involve-
ment of commercial sponsors. RESULTS: A total of 278 abstracts (19%) described
RW studies. Data were derived from a database in 55.8%, health service/patient
medical records in 24.8%, surveys/questionnaires in 15.8% and other sources in
3.6%. 12% were conducted in the UK; a further 8% included UK centres in an inter-
national study. 24% were conducted in the USA, 53% in another country (not UK,
not USA – 38 countries, most commonly Spain 6%, Canada 5%, Germany 5%, France
5%, The Netherlands 3% and Italy 3%) and 3% were international without a UK
centre. In 21% of abstracts there was a UK author. CONCLUSIONS: RW studies
presented at the ISPOR European Congress 2011 were most often single country
rather than international with the USA being the most prolific source. Of the rest,
the UK was the source of RW data in twice as many studies as any other country,
lending weight to the opinion that the UK provides an excellent environment for
conducting RW studies.
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OBJECTIVES: It is widely recognized that regular exercise improves fitness, with
increasing evidence that physical activity (PA; movement resulting in elevated
energy expenditure beyond basal levels) can affect health, particularly in chronic
disease. While pharmacologic therapy and exercise training have been shown to
improve capacity, persistent increase in PA requires behavior change. This review
examined studies testing the effectiveness of behavioral interventions to increase
PA in adults with chronic disease. METHODS: Embase and PubMed searches of
intervention studies published in English, 1995-2011. Inclusion criteria: Adults 45
years; COPD, diabetes, heart failure, obesity; exercise or PA endpoint; behavioral
intervention described in sufficient detail to permit interpretation. RESULTS: A
total of 932 abstracts screened; 169 articles retrieved; 36 reviewed. Most were ran-
domized trials (n30, 83%) with 2 intervention arms (n29, 81%), medium to high
quality (n34, 94%). Subjects were recruited through clinical settings (n28, 78%),
with disease severity a primary eligibility criterion (n23, 64%); 15 (42%) had sam-
ple sizes 40-100. Mean study duration  9.6 months (range: 1-84). Exercise inter-
vention: 30-50 minutes aerobic activity 3-5 times/week (n22, 61%); 64% included
walking. Instruction was individual (n25, 69%), initially supervised (n24, 67%)
followed by unsupervised home exercise (n15, 42%). Behavioral intervention:
counseling (n19, 53%) with personal contact follow-up (n12, 33%). Control
group: exercise without behavioral intervention (n14, 39%) or usual care (n15,
42%). Significant effects of the intervention were reported in 15 of 25 (60%) studies
testing exercise capacity (6-minute walk, cycle or treadmill), 19 of 26 (73%) testing
PA outcomes (pedometer, activity log, questionnaire), 11 of 22 (50%) measuring
HRQL, and 8 of 13 (62%) capturing behavioral endpoints. CONCLUSIONS: This re-
view provides insight into the range of designs, interventions, and outcome mea-
sures used in studies testing methods to improve PA in chronic disease. Results
identify promising interventions, with implications for improving research meth-
ods and outcomes.
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OBJECTIVES: Guidelines for treatment of rheumatoid arthritis (RA) advise initial
therapy with non-biological disease modifying antirheumatic drugs (DMARDs). In
case patients do not respond adequately, treatment should be switched to biologic
DMARDs. Aim of this research is to compare results of public available systematic
reviews (SRs) on comparative effectiveness (CER) and potential impact of differ-
ences in methodology. METHODS: We performed literature research for SR on CER
of biologics for the treatment of RA. Search was limited to reviews published in
2009 or later. Methods of the reviews and results were extracted from the publica-
tions. Results are summarized in narrative way and differences in results are re-
flected focusing on methodological key issues. RESULTS: Eleven recent SRs were
identified addressing the question of CER of biologics. Since there are no head-to-
head comparisons available for all but one biologic, reviews had to use indirect
comparisons to assess CER. Authors used the Simon-Bucher approach or Bayesian
methods (mixed treatment comparisons). Clinical trial guidelines for RA give the
advice to use Response Criteria defined according to the American College of Rheu-
matology (ACR) as primary parameter. Therefore, all trials assessed ACR20 (20%
improvement), ACR50 and ACR70 and could be used for comparison. Further pa-
rameters were not assessed in a uniform manner (e.g. quality of life) or not as-
sessed in all trials (e.g. disease activity score) and therefore could not be used for
indirect comparison of treatments. CONCLUSIONS: Due to lack of head-to-head
data for comparison of biologics, statistical methods for indirect comparison have
to be used to answer the question of CER. These methods have restrictions and base
on assumptions that might be heavily violated. Substances were tested over a time
period of more than 10 years with effects on study population and variation in
study designs. Nevertheless, the results seem to be fairly consistent.
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OBJECTIVES:Clostridium difficileinfection (CDI) has been found to be associated with
increased inpatient length of stay (LoS), however the causal direction is unclear.
Many have attempted to correct for potential endogeneity bias by case matching
patients at the hospital level or by using instrumental variable regressions. We
propose an alternative method using propensity score matching on a nationwide
dataset to isolate the added effect of the disease using hospital level data.
METHODS: Using the Hospital Episode Statistics (HES) dataset for England, four
propensity scoring techniques were tested to estimate the causal effect of CDI on
LoS of patients over 50 years old, who have been diagnosed with diabetes, chronic
obstructive pulmonary disorder (COPD), heart failure, and/or chronic kidney dis-
ease. Methodological variations include radius matching, nearest neighbour
matching with and without replacement, and kernel matching. RESULTS: Control-
ling for a number of covariates, nearest neighbour matching with replacement
produces the least biased and most consistent estimates at 15.22 days longer LoS
after contracting CDI, with a post-matching pseudo-R2value of zero and a mean
absolute standardized bias of 0.51% compared to 41.53% before matching. Radius
matching produces less consistent results at 17.05 days, with a mean standardized
bias of 2.93% after matching. Kernel matching does not adequately account for bias
likely due to the largely unbalanced nature of the treatment versus control group.
CONCLUSIONS: Propensity score matching serves as an alternative method to tra-
ditional regression approaches to estimate the causal effect of CDI on patient LoS.
The results are consistent with those previously derived in the literature and dem-
onstrate the heavy burden of CDI on the English National Health Service.
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OBJECTIVES: Veterans Administration Corporate Data Warehouse stores data-
bases with standardized structure that could be used for automated data extrac-
tion, reviewer abstraction, and text mining to determine the association between
health outcomes and disease-specific factors. This retrospective study provides
assessment of VA administrative data used to examine the impact of pharmaco-
logical therapy on complications in ulcerative colitis (UC). METHODS: Previous
studies investigating the effect of 5ASA on the risk for colorectal cancer (CRC) in UC
patients have reported conflicting results. We obtained nationwide UC and CRC
data from VA health care system for the period 2001-2011. Secondary relational
databases were searched for clinical variables based on standardized criteria - ICD9
diagnoses, procedural and medication codes. Data extraction captured demo-
graphics, clinical information and pharmacy record for a cohort of 37,191 UC cases.
We constructed a dataset of potential ulcerative colitis cases with CRC (n1,087)
defined by ICD9 codes 556.x for UC, and 153.x,154.x and 159.0 for CRC. A random
subsample of 100 non-5ASA users with CRC was compared to 100 controls without
CRC. RESULTS: Diagnosis of ICD9 code for CRC had PPV 79% and NPV 100% in the
random sample. Within the 1087 potential CRC cases, only 500 (46%) were found to
have evidence of both conditions on chart review with kappa agreement between
automated and manual abstraction 0.73 (95% CI: 0.70-0.76) for CRC and significantly
lower for UC - 0.60 (95% CI: 0.57-0.63). The initial overall prevalence of CRC in the UC
cohort was 2.9% and decreased to 1.34% after human text search verification.
CONCLUSIONS: Automated extracts have great potential for diseases surveillance
but manual review yields more reliable data. Pre-defined diagnostic algorithms
based on a combination of methods as well as further technology development like
natural language processing and longitudinal patient record will improve accuracy
of retrospective databases.
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OBJECTIVES: Real-world data is considered to be the gold standard by decision
makers to inform on cost-effectiveness of new drugs. Unfortunately real-world
data are often lacking in important parameters needed to inform on cost-effective-
ness, and RCT data can be used to address this problem. Illustrated by two cases
this abstract will show that the manner in which RCT and real-world data are
combined can have a profound influence on the resulting ICER. METHODS: Two
case studies in which real-world data on cetuximab for the indication of locally
advanced head and neck cancer and panitumumab for the indication of chemo-
refractory metastatic colorectal cancer was collected retrospectively served as
examples. RESULTS: The problem: In the case of cetuximab, patient selection in
daily practice resulted in too much disparity in baseline characteristics between
the treated and control group. The solution: survival data for both treatment
groups from the pivotal RCT was used and corrected according to the results seen
in the real-world data to better represent survival in daily practice. Using unad-
justed RCT data resulted in a difference of approximately 5,000 euro/QALY in the
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ICER. In the case of panitumumab no data were available on progression of disease
in the control group. The solution: progression free survival and survival after
progression of the control group were drawn from the pivotal RCT and adjusted
according to the survival observed in the control group of the outcomes research.
Unadjusted RCT data resulted in an ICER that was approximately 20,000 euro/QALY
higher. CONCLUSIONS: RCT data are often necessary to supplement missing data
that cannot be collected through outcomes research, however the manner in which
RCT data is used can have a profound effect on the resulting cost-effectiveness.
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OBJECTIVES: In cancer, treatments often aim to extend time to progression. The
implications on overall survival are often inconclusive, as trials are too short and
the majority of patients are still alive at the end of the trial. However, for decision
making, it is important to estimate both the treatment effect on Progression Free
Survival as well as the treatment effect on Overall Survival. This poster shows how
the estimation of Overall Survival benefit can be improved by the use of Progression
Free Survival data. METHODS: The developed Network Meta-Analysis model uses
the tested hypothesis that treatments provided until progression in general do not
change the length of the post-progression period. This hypothesis is tested in detail
based on systematic literature reviews concerning 4 different types of cancer. A
test for equal lengths of the post-progression periods is described too. RESULTS: A
network meta-analysis model is described, which can be used to obtain estimates
for OS from PFS data for treatments for which no OS data or insufficient OS data are
available. This informs decision making in situations where otherwise no conclu-
sion can be drawn. The methodology is applied to an indirect comparison of
Chlorambucil, Fludarabine and Fludarabine Cyclophosphamide. Comparable DIC
were obtained to individual fitting of OS and PFS for the situation that OS data were
available. Therefore, the methodology both enables the fitting of OS when OS data
are not available as well as potentially improves OS fitting when data are limited
available. CONCLUSIONS: Based on systematic literature reviews, a method is de-
veloped to use PFS as surrogate outcome for OS. In addition, a test is developed to
justify the assumption of equal post-progression periods among treatments, which
can be used to assess whether the translation of PFS time differences in OS time
differences is appropriate.
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OBJECTIVES: We aimed to assess statistical methods for adjusting survival esti-
mates in the presence of treatment crossover in order to identify which are the
most appropriate in a range of scenarios. Treatment crossover is a common issue in
clinical trials of cancer treatments. Crossover occurs when patients in the control
group switch onto the experimental treatment at some point during follow-up. In
such circumstances an intention to treat (ITT) analysis does not address the deci-
sion problem faced by health technology assessment bodies, and will result in
biased estimates of the overall survival advantage – and therefore the cost-effec-
tiveness – associated with the experimental treatment. METHODS: We conducted
a simulation study to assess the performance of crossover-adjustment methods in
a range of scenarios. We purposefully ran scenarios that did not satisfy the specific
assumptions made by the methods, in order to assess their sensitivities. RESULTS:
Randomisation-based methods (eg Rank Preserving Structural Failure Time Models
(RPSFTM) and Iterative Parameter Estimation (IPE)) were unbiased only when the
treatment effect was not time-dependent. Observational-based methods (eg In-
verse Probability of Censoring Weights (IPCW) and Structural Nested Models
(SNMs) with g-estimation) coped better with time-dependent treatment effects but
are heavily data reliant, are sensitive to model misspecification and often produced
high levels of bias in our simulations. Observational-based methods are particu-
larly sensitive to the proportion of control group patients that crossover whereas
randomisation-based methods are not. CONCLUSIONS: Currently available rando-
misation-based and observational-based methods for addressing treatment cross-
over have important limitations. However, in most circumstances they are likely to
lead to lower bias than an ITT analysis, given the decision problem faced in an
economic evaluation. Analysts should consider the treatment crossover mecha-
nism, the control group crossover proportion, the treatment effect associated with
different patient groups, and data availability when deciding which method to use
to address treatment crossover.
RESEARCH ON METHODS - Cost Methods
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OBJECTIVES: Some European health authorities such as the National Institute of
Clinical Excellence in the UK have published Health Technology Assessment (HTA)
guidelines, which recommend the use of the Quality Adjusted Life Years (QALYs)
outcome measure as the reference case. The ECHOUTCOME project is an interdis-
ciplinary European research platform funded by the seventh Framework Program
of the European Commission which objectives are to assess the validity of the
QALYs for its potential use in cost effectiveness analysis (CEA) in European coun-
tries and proposing new European guidelines for conducting CEA studies.
METHODS: Over a period of 3 months, a total of 1,200 students from Belgium,
France, Italy and the UK answered hypothetical health states in which the health
states and time in a given health states were varied in order to test for: von Neu-
maniann-Morgesten assumptions, mutual independence in utility, and the rele-
vance of the multi-linear multi-attribute utility theory, which are the basis for the
QALY calculation, as currently performed in the HTA literature. RESULTS: The
preliminary findings of the experiment provided strong evidence that utilities ob-
tained by varying the health states and the duration of a given health state fail to
comply with the theoretical basis of the QALY. CONCLUSIONS: The results suggest
that the underlying assumptions of the QALY calculation model are not in line with
behavior from a real life population, implying that the QALY outcome measure
might not be a valid measure for supporting health decision making in Europe. The
findings of this first European experimental survey testing the validity of the QA-
LYoutcome measure should be considered by European member states before rec-
ommending such approach in HTA guidelines.
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OBJECTIVES: The World Health Organisation (WHO) Guide to Identify the Eco-
nomic Consequences of Disease and Injury described the financial burden of poor
health for government both in terms of increased transfer costs and lost tax reve-
nue due to reduced productivity. To evaluate the broader consequences of rotavi-
rus we developed a quantitative “government perspective” framework to evaluate
immunisation costs in Ghana. METHODS: Methods from generational accounting,
human capital economics and epidemiologic modelling were combined to esti-
mate the benefits of rotavirus vaccination in terms of measures used in financial
analyses such as the Net Present Value (NPV) and Return on Investment (ROI). Data
from the published literature and national statistical sources were collected. Single
and multiple cohort models were developed simulating survival, direct medical
costs and average lifetime fiscal transfers between the government and individuals
with and without the vaccination until the age of 65 years. Direct and indirect tax
rates were linked to differences in lifetime age-specific earnings to quantify the tax
revenue associated with vaccinated and unvaccinated individuals. RESULTS: From
a “government perspective” the results showed that every dollar invested on vac-
cination against rotavirus, may yield a discounted gross tax ROI equal to $2.9 and a
net tax ROI of $0.55. The vaccinated and unvaccinated cohorts resulted in total
lifetime discounted net tax of -$167 million -$174 million, for the vaccinated and
unvaccinated cohorts, respectively. The results suggested a net fiscal benefit of
approximately $7million and $54 million for the single and multiple birth cohorts,
respectively. CONCLUSIONS: Vaccinating against rotavirus may result in consid-
erable fiscal benefits. Investments in vaccinations may influence future govern-
ment tax revenue and thus contribute to the sustainability of tax-financed health
systems, public finances and economic growth. Estimating the broader economic
impact of vaccines using the “government perspective” framework may inform
cross-sectoral governmental resource allocation decisions.
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OBJECTIVES: There is a great heterogeneity across health economic studies with
regard to claim of cost inputs making comparison of costs complicated. Objective
was to analyze data availability, corresponding limitations and improvement
approaches. METHODS: We evaluate the availability of cost data capture for Ger-
many, Spain, France and USA. In Germany data from the Hospital Remuneration,
the German Hospital Society (DKG) and the two outpatient tariffs were considered
as well as Medicare, Medicaid and HCUP databases for USA, Database of Ministry of
Health and regional/national official bulletins for Spain and lastly data from SNI-
RAM (Social Security information system) and PMSI (Programme de médicalisation
des systèmes d’information) for France. RESULTS: DRG database in Germany and
USA reflect the reimbursement level more than real cost per indication. Fragmen-
tation of these costs is not possible. The DKG normal tariff (DKG-NT) is listing
detailed procedures and services used for example for reimbursement between
two hospitals. The Spanish inpatient cost data are difficult to collect due to the
prospective hospital global budget; health authorities publish annually DRG and
outpatient procedure tariffs as reference of their own resources cost. In France
SNIRAM data is limited to Social Security own needs. In contrast publicly available
PMSI data allows inpatient information tracking related to specific medical proce-
dure use.Regarding outpatient setting, the physician fee schedule is based on the
Uniform Evaluation Scale (EBM) and the medical fee schedule (GOA¨) for SHI and
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